Literature DB >> 29915156

Disposition of Methamphetamine and Major Metabolites in Mice: Role of Organic Cation Transporter 3 in Tissue-Selective Accumulation of Para-Hydroxymethamphetamine.

David J Wagner1, Laura M Shireman1, Sojung Ahn1, Danny D Shen1, Joanne Wang2.   

Abstract

Methamphetamine is one of the most widely abused illicit drugs. Although human intoxication and multiple tissue toxicities frequently occur in abusers, little is known about the distribution of methamphetamine or its primary metabolites, amphetamine and para-hydroxymethamphetamine (p-OHMA), to their sites of toxicity. This study determined the pharmacokinetics, tissue exposure, and partition ratios of methamphetamine and major metabolites in various mouse tissues and investigated the impact of organic cation transporter 3 (Oct3) following i.v. injection of methamphetamine to male Oct3+/+ and Oct3-/- mice. Methamphetamine, amphetamine, and p-OHMA were readily detectable in plasma with Oct3+/+ and Oct3-/- mice displaying similar plasma pharmacokinetic profiles for all three analytes. In addition to kidney and liver, salivary glands highly accumulated methamphetamine, amphetamine, and p-OHMA with total exposure 3.3- to 9.4-fold higher than plasma area under the concentration-time curve (AUC). Consistent with being an Oct3 substrate, p-OHMA AUC in salivary glands is reduced by 50% in Oct3-/- mice. p-OHMA AUC in skeletal muscle is also significantly reduced in Oct3-/- mice. Our data identified salivary glands as a novel site of high accumulation of methamphetamine and metabolites, which may underlie methamphetamine toxicity in this tissue. Furthermore, our study identified Oct3 as an important determinant of tissue uptake and exposure to p-OHMA in salivary glands and skeletal muscle. Our findings suggest that local tissue accumulation of methamphetamine and/or its metabolites may play a role in several of the reported peripheral toxicities of methamphetamine, and Oct3 can significantly impact tissue exposure to its substrates without affecting systemic elimination.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29915156      PMCID: PMC6081671          DOI: 10.1124/dmd.118.082131

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  31 in total

1.  Inhibitory and facilitory actions of isocyanine derivatives at human and rat organic cation transporters 1, 2 and 3: a comparison to human alpha 1- and alpha 2-adrenoceptor subtypes.

Authors:  Anne Amphoux; Mark J Millan; Alex Cordi; Heinz Bönisch; Vincent Vialou; Clotilde Mannoury la Cour; Delphine S Dupuis; Bruno Giros; Sophie Gautron
Journal:  Eur J Pharmacol       Date:  2010-02-17       Impact factor: 4.432

2.  Resampling methods in sparse sampling situations in preclinical pharmacokinetic studies.

Authors:  H Mager; G Göller
Journal:  J Pharm Sci       Date:  1998-03       Impact factor: 3.534

3.  Methamphetamine abuse and oral health: a pilot study of "meth mouth".

Authors:  Michele C Ravenel; Carlos F Salinas; Nicole M Marlow; Elizabeth H Slate; Zachary P Evans; Peter M Miller
Journal:  Quintessence Int       Date:  2012-03       Impact factor: 1.677

4.  Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3.

Authors:  Haichuan Duan; Joanne Wang
Journal:  J Pharmacol Exp Ther       Date:  2010-09-21       Impact factor: 4.030

5.  Interaction of organic cation transporter 3 (SLC22A3) and amphetamine.

Authors:  Hao-Jie Zhu; David I Appel; Dirk Gründemann; John S Markowitz
Journal:  J Neurochem       Date:  2010-04-06       Impact factor: 5.372

Review 6.  Methamphetamine abuse and dentistry.

Authors:  D T Hamamoto; N L Rhodus
Journal:  Oral Dis       Date:  2008-09-25       Impact factor: 3.511

Review 7.  Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.

Authors:  Rafael de la Torre; Magí Farré; Mónica Navarro; Roberta Pacifici; Piergiorgio Zuccaro; Simona Pichini
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway.

Authors:  Mei Cui; Radha Aras; Whitney V Christian; Phillip M Rappold; Mamata Hatwar; Joseph Panza; Vernice Jackson-Lewis; Jonathan A Javitch; Nazzareno Ballatori; Serge Przedborski; Kim Tieu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-29       Impact factor: 11.205

9.  Distribution of organic cation transporter 3, a corticosterone-sensitive monoamine transporter, in the rat brain.

Authors:  Paul J Gasser; Miles Orchinik; Ilangovan Raju; Christopher A Lowry
Journal:  J Comp Neurol       Date:  2009-02-01       Impact factor: 3.215

Review 10.  Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications.

Authors:  Hermann Koepsell; Katrin Lips; Christopher Volk
Journal:  Pharm Res       Date:  2007-05-01       Impact factor: 4.580

View more
  8 in total

Review 1.  Methamphetamine Dysregulation of the Central Nervous System and Peripheral Immunity.

Authors:  Douglas R Miller; Mengfei Bu; Adithya Gopinath; Luis R Martinez; Habibeh Khoshbouei
Journal:  J Pharmacol Exp Ther       Date:  2021-09-17       Impact factor: 4.402

2.  Development and validation of a LC-MS/MS method for in vivo quantification of meta-iodobenzylguanidine (mIBG).

Authors:  Antonio J López Quiñones; Laura M Shireman; Joanne Wang
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2021-09-03       Impact factor: 3.318

3.  Clinical Applications and the Roles of Transporters in Disposition, Tumor Targeting, and Tissue Toxicity of meta-Iodobenzylguanidine (mIBG).

Authors:  Antonio J Lopez Quiñones; Leticia Salvador Vieira; Joanne Wang
Journal:  Drug Metab Dispos       Date:  2022-02-22       Impact factor: 3.579

4.  Characterization of Meta-Iodobenzylguanidine (mIBG) Transport by Polyspecific Organic Cation Transporters: Implication for mIBG Therapy.

Authors:  Antonio J López Quiñones; David J Wagner; Joanne Wang
Journal:  Mol Pharmacol       Date:  2020-06-02       Impact factor: 4.436

Review 5.  The Interaction of Organic Cation Transporters 1-3 and PMAT with Psychoactive Substances.

Authors:  Julian Maier; Marco Niello; Deborah Rudin; Lynette C Daws; Harald H Sitte
Journal:  Handb Exp Pharmacol       Date:  2021

6.  Comparative Neuropharmacology and Pharmacokinetics of Methamphetamine and Its Thiophene Analog Methiopropamine in Rodents.

Authors:  Silja Skogstad Tuv; Marianne Skov-Skov Bergh; Jannike Mørch Andersen; Synne Steinsland; Vigdis Vindenes; Michael H Baumann; Marilyn A Huestis; Inger Lise Bogen
Journal:  Int J Mol Sci       Date:  2021-11-05       Impact factor: 5.923

7.  Membrane Transporters in Human Parotid Gland-Targeted Proteomics Approach.

Authors:  Joanna Lapczuk-Romanska; Diana Busch; Ewa Gieruszczak; Agnieszka Drozdzik; Katarzyna Piotrowska; Robert Kowalczyk; Stefan Oswald; Marek Drozdzik
Journal:  Int J Mol Sci       Date:  2019-09-28       Impact factor: 5.923

8.  Methamphetamine enhances caveolar transport of therapeutic agents across the rodent blood-brain barrier.

Authors:  Jui-Hsien Chang; Chris Greene; Karen Frudd; Leonardo Araujo Dos Santos; Clare Futter; Benjamin J Nichols; Matthew Campbell; Patric Turowski
Journal:  Cell Rep Med       Date:  2022-01-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.